1. Home
  2. VBNK vs RIGL Comparison

VBNK vs RIGL Comparison

Compare VBNK & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VBNK
  • RIGL
  • Stock Information
  • Founded
  • VBNK 1980
  • RIGL 1996
  • Country
  • VBNK Canada
  • RIGL United States
  • Employees
  • VBNK N/A
  • RIGL N/A
  • Industry
  • VBNK Commercial Banks
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • VBNK Finance
  • RIGL Health Care
  • Exchange
  • VBNK Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • VBNK 441.5M
  • RIGL 366.5M
  • IPO Year
  • VBNK 2021
  • RIGL 2000
  • Fundamental
  • Price
  • VBNK $10.25
  • RIGL $18.21
  • Analyst Decision
  • VBNK Strong Buy
  • RIGL Buy
  • Analyst Count
  • VBNK 3
  • RIGL 5
  • Target Price
  • VBNK $19.00
  • RIGL $36.80
  • AVG Volume (30 Days)
  • VBNK 91.0K
  • RIGL 232.8K
  • Earning Date
  • VBNK 03-05-2025
  • RIGL 03-04-2025
  • Dividend Yield
  • VBNK 0.70%
  • RIGL N/A
  • EPS Growth
  • VBNK N/A
  • RIGL N/A
  • EPS
  • VBNK 0.89
  • RIGL 0.99
  • Revenue
  • VBNK $75,813,751.00
  • RIGL $179,278,000.00
  • Revenue This Year
  • VBNK $31.26
  • RIGL $14.19
  • Revenue Next Year
  • VBNK $40.97
  • RIGL $13.10
  • P/E Ratio
  • VBNK $13.97
  • RIGL $17.32
  • Revenue Growth
  • VBNK N/A
  • RIGL 54.71
  • 52 Week Low
  • VBNK $9.48
  • RIGL $7.48
  • 52 Week High
  • VBNK $18.38
  • RIGL $29.82
  • Technical
  • Relative Strength Index (RSI)
  • VBNK 38.22
  • RIGL 41.05
  • Support Level
  • VBNK $9.76
  • RIGL $16.90
  • Resistance Level
  • VBNK $10.41
  • RIGL $19.97
  • Average True Range (ATR)
  • VBNK 0.29
  • RIGL 1.06
  • MACD
  • VBNK 0.12
  • RIGL -0.24
  • Stochastic Oscillator
  • VBNK 55.68
  • RIGL 30.54

About VBNK VersaBank

VersaBank is a Canadian Schedule I chartered bank with a difference. It has 3 operating segments: Digital Banking Canada, Digital Banking USA and DRTC. It's, cloud-based, business-to-business deposit and lending model provides valued-added solutions to Canadian financial intermediary partners, enabling them to focus on growing their own businesses faster and more profitably. It obtains all of its deposits and provides the majority of its loans and leases electronically, with deposit and lending solutions for financial intermediaries that allow them to excel in their core businesses. In addition, leveraging its internally developed IT security software and capabilities, Company established a wholly owned, subsidiary. Geographically located in Canada and USA.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: